Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928537 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
A Phase 3 study, sponsored by Traws Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 67
- Enrollment target
NCT01928537 is a Phase 3 study that has completed, run by Traws Pharma. The registered enrollment target is 67 participants.
The verdict
NCT01928537, a Phase 3 study, has completed, sponsored by Traws Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 67 participants
- Enrollment target
Study Summary
This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after treatment with azacitidine or decitabine.
Interventions
- DRUG rigosertib sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01928537
The ClinicalTrials.gov registry entry for NCT01928537 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Traws Pharma, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rigosertib sodium is the first listed.
NCT01928537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01928537 about?
NCT01928537 is a clinical study titled "Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine". This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after treatment with azacitidine or decitab...
What is the current status of trial NCT01928537?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 67 participants. The study started on 2013-08. Estimated completion is 2017-06-29.
What interventions are being tested in trial NCT01928537?
The interventions under investigation include: rigosertib sodium (DRUG).
Who is sponsoring clinical trial NCT01928537?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.